![Artur Plonowski](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Artur Plonowski is the founder of three companies.
He is the Chief Scientific Officer & Director at Seal Rock Therapeutics, Inc., the Chief Medical Officer at Orphinic Scientific SA, and the Chief Executive Officer at Vasa Therapeutics, Inc.
Aktive Positionen von Artur Plonowski
Unternehmen | Position | Beginn |
---|---|---|
Seal Rock Therapeutics, Inc.
![]() Seal Rock Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Seal Rock Therapeutics, Inc. develops molecule inhibitors apoptosis, inflammation and fibrosis. The company was founded by Kathleen Elias, Neil McDonnell and Artur Plonowski is headquartered in Seattle, WA. | Gründer | - |
Orphinic Scientific SA
![]() Orphinic Scientific SA BiotechnologyHealth Technology Orphinic Scientific engages in the development and delivery of pharmaceutical drugs for the treatments of rare diseases. The firm also provides research and development services. The company was founded by and is headquartered in Rome, Italy. | Gründer | - |
Vasa Therapeutics, Inc.
![]() Vasa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vasa Therapeutics, Inc. is a private biotechnology company based in Encinitas, CA, committed to discovering and developing transformative therapies for vascular diseases such as heart failure, peripheral artery disease, and sarcopenia. The company's cutting-edge computational chemistry and design platform integrates everything from the identification of viable biological targets to the design and identification of small molecule or peptide therapeutics. Vasa has three active preclinical programs, two small molecule programs focused on the treatment of cardiovascular disease and one peptide therapeutic program aimed at identifying a novel treatment for peripheral artery disease and sarcopenia. The company has a world-class, founder-led team with an outstanding track record of successful development of numerous clinical candidates and commercial drugs spanning multiple therapeutic areas and modalities resulting in several exits values at greater than $1b (USD). The CEO of the company is Mark Robert Herbert. | Vorstandsvorsitzender | 01.10.2019 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Seal Rock Therapeutics, Inc.
![]() Seal Rock Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Seal Rock Therapeutics, Inc. develops molecule inhibitors apoptosis, inflammation and fibrosis. The company was founded by Kathleen Elias, Neil McDonnell and Artur Plonowski is headquartered in Seattle, WA. | Health Technology |
Orphinic Scientific SA
![]() Orphinic Scientific SA BiotechnologyHealth Technology Orphinic Scientific engages in the development and delivery of pharmaceutical drugs for the treatments of rare diseases. The firm also provides research and development services. The company was founded by and is headquartered in Rome, Italy. | Health Technology |
Vasa Therapeutics, Inc.
![]() Vasa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Vasa Therapeutics, Inc. is a private biotechnology company based in Encinitas, CA, committed to discovering and developing transformative therapies for vascular diseases such as heart failure, peripheral artery disease, and sarcopenia. The company's cutting-edge computational chemistry and design platform integrates everything from the identification of viable biological targets to the design and identification of small molecule or peptide therapeutics. Vasa has three active preclinical programs, two small molecule programs focused on the treatment of cardiovascular disease and one peptide therapeutic program aimed at identifying a novel treatment for peripheral artery disease and sarcopenia. The company has a world-class, founder-led team with an outstanding track record of successful development of numerous clinical candidates and commercial drugs spanning multiple therapeutic areas and modalities resulting in several exits values at greater than $1b (USD). The CEO of the company is Mark Robert Herbert. | Health Technology |